More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$10.37B
EPS
-0.2
P/E ratio
--
Price to sales
10.84
Dividend yield
--
Beta
1.116803
Previous close
$162.78
Today's open
$162.78
Day's range
$160.27 - $165.34
52 week range
$100.99 - $198.87
show more
CEO
Olivier Loeillot
Employees
2000
Headquarters
Waltham, MA
Exchange
Nasdaq Global Select
Shares outstanding
63923738
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Repligen Corporation (RGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Repligen Corporation (RGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • 6 hours ago

AMG TimesSquare Small Cap Growth Fund Q3 2026 Portfolio Activity
During this quarter, AMG TimesSquare Small Cap Growth Fund outperformed the Russell 2000® Growth Index as the market rewarded the quality characteristics our process emphasizes. We benefited most from our holdings in the Information Technology, Financials, and Consumer Staples sectors, while positioning in the Industrials, Health Care, and Consumer Discretionary sectors offset part of the gain. Each of our largest contributors was driven by company-specific fundamentals, including solid results and business momentum, and, in two cases, making acquisitions we viewed as strategically or financially attractive.
Seeking Alpha • Nov 15, 2026

Voya Small Cap Growth Strategy Q3 2026 Contributors And Detractors
For the quarter ended September 30, 2026, the Fund underperformed the Index on a NAV basis, due to stock selection. Negative stock selection in the industrials, financials, and materials sectors was the leading detractor from performance along with an overall negative allocation effect. Stock selection in the consumer staples and real estate sectors and holding cash were the largest contributors to performance.
Seeking Alpha • Nov 12, 2026

Alger Mid Cap 40 ETF Q3 2026 Portfolio Review
Twist Bioscience Corp., Cloudflare Inc., and Repligen Corporation were among the top contributors to performance. We believe Cloudflare's extensive network and expanding product portfolio position it to benefit from rising internet traffic, growing cybersecurity needs, and enterprise adoption of AI. FTAI shares detracted from performance during the quarter despite continued growth in its engine products business and progress on adapting mature aircraft engines for data center power generation.
Seeking Alpha • Nov 12, 2026

Repligen: 3 Key Takeaways for Long-Term Investors
Repligen delivered revenue of $209 million in the third quarter. BioLife is expected to contribute $24 million in fourth-quarter revenue.
The Motley Fool • Nov 5, 2026

Repligen Corporation to Present at Jefferies Global Healthcare Conference
WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst-led discussion on November 18th at 2:00 p.m. GMT.
GlobeNewsWire • Nov 4, 2026

Baron SMID Cap ETF Q3 2026 Contributors And Detractors
Baron SMID Cap ETF returned -2.87% (NAV) in the third quarter, outperforming its benchmark, the Russell 2500 Growth Index, which returned -10.35%. Top contributors were Rubrik, Inc., Tempus AI, Inc., and Netskope, Inc. Top detractors were Axon Enterprise, Inc., Forgent Power Solutions, Inc., and Mercury Systems, Inc.
Seeking Alpha • Nov 3, 2026

Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 1.00% Convertible Senior Notes due 2028 (the “2028 Notes”) and certain new investors, pursuant to which Repligen will issue $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031 (the “New Notes”). Approximately $541.4 million principal amount of the New Notes will be issued in exchange for approximately $456.8 million principal amount of 2028 Notes (the “Exchange Transactions”) and approximately $458.6 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”). The conversion price for the New Notes will initially be approximately $226.37 per share of Repligen's common stock, which represents a conversion premium of approximately 20% over the closing price of Repligen's common stock on October 29, 2026, subject to customary anti-dilution adjustments. Following the closing of the Transactions, which is expected to occur on or about November 6, 2026, subject to customary closing conditions, approximately $143.2 million in aggregate principal amount of 2028 Notes will remain outstanding with terms unchanged.
GlobeNewsWire • Oct 30, 2026

Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells
We remain encouraged by the operational performance of the Micro cap companies held in portfolios. TWST shares surged as a strong fiscal 3Q highlighted accelerating demand across several of the company's end markets. TKNO management responded to the stronger first half by substantially raising its full-year revenue outlook.
Seeking Alpha • Oct 30, 2026

What Repligen (RGEN) Said on Its Q3 Earnings Call
Repligen NASDAQ: RGEN reported record third-quarter 2026 revenue of $209 million, surpassing its prior quarterly peak set in the second quarter of 2022, as growth in its Proteins, Chromatography and Analytics franchises offset weakness in Filtration.
MarketBeat • Oct 27, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Repligen Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.